StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)

Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –

Rallybio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Rallybio's ebitda for the twelve months ending Sep 30, 2026 was -$24.21M. For fiscal 2025 it was -$32.97M. The highest annual figure on record is -$25.24M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.97M–
FY2024Dec 31, 2024-$60.37M–
FY2023Dec 31, 2023-$78.78M–
FY2022Dec 31, 2022-$67.72M–
FY2021Dec 31, 2021-$45.54M–
FY2020Dec 31, 2020-$25.24M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.42M–
Q2 FY2026Jun 30, 2026-$5.65M–
Q1 FY2026Mar 31, 2026-$8.73M–
Q4 FY2025Dec 31, 2025-$6.41M–
Q3 FY2025Sep 30, 2025-$6.89M–
Q2 FY2025Jun 30, 2025-$10.03M–
Q1 FY2025Mar 31, 2025-$9.64M–
Q4 FY2024Dec 31, 2024-$11.58M–
Q3 FY2024Sep 30, 2024-$12.03M–
Q2 FY2024Jun 30, 2024-$17.00M–
Q1 FY2024Mar 31, 2024-$19.75M–
Q4 FY2023Dec 31, 2023-$21.08M–
Q3 FY2023Sep 30, 2023-$19.33M–
Q2 FY2023Jun 30, 2023-$20.05M–
Q1 FY2023Mar 31, 2023-$18.34M–
Q4 FY2022Dec 31, 2022-$17.05M–
Q3 FY2022Sep 30, 2022-$18.82M–
Q2 FY2022Jun 30, 2022-$17.57M–
Q1 FY2022Mar 31, 2022-$14.28M–
Q4 FY2021Dec 31, 2021-$12.28M–
Q3 FY2021Sep 30, 2021-$9.96M–
Q2 FY2021Jun 30, 2021-$10.51M–
Q1 FY2021Mar 31, 2021-$12.80M–
Q4 FY2020Dec 31, 2020-$10.07M–
Q3 FY2020Sep 30, 2020-$6.70M–

More Rallybio figures

See a number that looks wrong?